Literature DB >> 20367227

Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus.

Georg Härter1, Oliver Zimmermann, Ludwig Maier, Axel Schubert, Thomas Mertens, Peter Kern, Jochen Wöhrle.   

Abstract

We report on 2 critically ill patients with pneumonitis and acute respiratory distress syndrome due to pandemic (H1N1) 2009 influenza A virus who were treated with intravenous zanamivir and had favorable clinical outcomes. Zanamivir given intravenously may be a therapeutic option in patients with critical illness and mechanical ventilation.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20367227     DOI： 10.1086/651604

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  14 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.

Authors:  Roy F Chemaly; Dimpy P Shah; Michael J Boeckh
Journal:  Clin Infect Dis       Date:  2014-11-15       Impact factor: 9.079

3.  Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.

Authors:  Ashley N Brown; James J McSharry; Qingmei Weng; Jonathan R Adams; Robert Kulawy; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

Review 4.  Two years after pandemic influenza A/2009/H1N1: what have we learned?

Authors:  Vincent C C Cheng; Kelvin K W To; Herman Tse; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

5.  Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects.

Authors:  Mark J Shelton; Mark Lovern; Judith Ng-Cashin; Lori Jones; Elizabeth Gould; Jennifer Gauvin; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

Review 6.  Detection and management of antiviral resistance for influenza viruses.

Authors:  Guy Boivin
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

7.  Management of respiratory viral infections in hematopoietic cell transplant recipients.

Authors:  Dimpy P Shah; Shashank S Ghantoji; Victor E Mulanovich; Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Am J Blood Res       Date:  2012-11-25

8.  Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection.

Authors:  P L A Fraaij; E van der Vries; M F C Beersma; A Riezebos-Brilman; H G M Niesters; A A van der Eijk; M D de Jong; D Reis Miranda; A M Horrevorts; B U Ridwan; M J H M Wolfhagen; R J Houmes; J T van Dissel; R A M Fouchier; A C M Kroes; M P Koopmans; A D M E Osterhaus; C A B Boucher
Journal:  J Infect Dis       Date:  2011-09-01       Impact factor: 5.226

9.  Recent advances in the diagnosis and treatment of influenza pneumonia.

Authors:  Lucia Marzoratti; Hernán A Iannella; Victoria Fernández Gómez; Sandra B Figueroa
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

10.  Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets.

Authors:  Erhard van der Vries; Koert J Stittelaar; Geert van Amerongen; Edwin J B Veldhuis Kroeze; Leon de Waal; Pieter L A Fraaij; Roland J Meesters; Theo M Luider; Bart van der Nagel; Birgit Koch; Arnold G Vulto; Martin Schutten; Albert D M E Osterhaus
Journal:  PLoS Pathog       Date:  2013-05-23       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.